Put companies on watchlist
DocMorris AG
ISIN: CH0042615283
WKN: A0Q6J0
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

DocMorris AG · ISIN: CH0042615283 · EQS - adhoc news (88 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1897901
08 May 2024 07:00AM

Daniel Wüest becomes new CFO at DocMorris


DocMorris AG / Key word(s): Personnel
DocMorris AG: Daniel Wüest becomes new CFO at DocMorris

08-May-2024 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Frauenfeld, 8 May 2024

Press release
Ad hoc announcement pursuant to Art. 53 LR

Daniel Wüest becomes new CFO at DocMorris

The Board of Directors of DocMorris AG has appointed Daniel Wüest to succeed Marcel Ziwica as CFO. Daniel Wüest will take over his new role on 1 October 2024.

Marcel Ziwica (49) will leave the company at his own request at the end of the year in order to reorient himself professionally after 23 years. Walter Oberhänsli, Chairman of the Board of Directors, commented: “We would like to express our sincere thanks to Marcel Ziwica. With him, a man from the very beginning is leaving the company, who has played a key role in all major projects of the last two decades and who has decidedly shaped the development of DocMorris. The company owes him a lot, both professionally and personally. We wish him all the best for his new start. With Daniel Wüest, DocMorris has been able to gain a competent successor and proven financial expert for this important position.”

The Swiss economist Daniel Wüest (54) has spent the last five years as Group CFO of the listed building supplier Arbonia, where he was actively involved in the strategic and financial realignment of the Group through acquisitions and disposals. Prior to that, Daniel Wüest worked for UBS for more than twenty years in various investment banking positions, where he advised on numerous mergers, acquisitions, debt and equity financings, and IPOs.

CEO Walter Hess is pleased about the new member of the Executive Board: “Daniel Wüest is a proven expert in corporate finance. His broad background of experience in the international corporate environment as well as in financial management and capital markets is extremely valuable to us. I am very much looking forward to working with him. I would like to express my sincere thanks to Marcel Ziwica for his excellent contribution, which is characterised by mutual respect and appreciation, which we will continue until his departure.”

 

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

20 August 2024 2024 Half-year results (conference call/webcast)
15 October 2024 Q3/2024 Trading update

 

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. The company was renamed from Zur Rose Group AG to DocMorris AG in May 2023 after the Swiss business was sold to Migros/Medbase. Excluding the Swiss business, about 1,600 employees in Germany, the Netherlands, Spain, France and Switzerland generated an external revenue of CHF 1,038 million serving over 9 million active customers in 2023. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

 



End of Inside Information
Language: English
Company: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1897901

 
End of Announcement EQS News Service

1897901  08-May-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1897901&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - DocMorris AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.